Two independent advances sharpen the therapeutic promise of genetic medicines. A dual AAV split‑base‑editor system (TeABE) achieved targeted in‑vivo editing of Chd3 in mouse brain, reversing disease‑relevant behavioral phenotypes and demonstrating a path for correcting neurological disorders at their genetic roots. Separately, UCLA researchers reported a lipid nanoparticle (LNP) platform that inserts a full‑length healthy gene into human airway cells, addressing size limits that have constrained universal gene replacement strategies for diseases such as cystic fibrosis. Both studies report preclinical efficacy and delivery innovations; LNP‑mediated full‑gene insertion and compact base editors represent complementary routes to expand the scope of genome therapy.